The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)
- 16 September 2007
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 30 (6) , 924-934
- https://doi.org/10.1007/s10545-007-0641-8
Abstract
Mucopolysaccharidosis II (MPS II, Hunter syndrome in humans) is an X-linked inherited lysosomal storage disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (I2S). I2S catalyses a step in the catabolism of glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, and when it is deficient or absent GAGs accumulate in tissues and organs. Male knockout mice (IdS-KO), which lack the gene coding for I2S, exhibit many of the characteristics seen in the human disease. Compared to wild-type control mice, urine GAG excretion was elevated at 4 weeks of age and remained high throughout the lifespan, and tissue GAG levels were elevated as early as 7 weeks of age. Liver, spleen and other organs were significantly larger in the IdS-KO mice than in the wild-type. Radiographic examination revealed sclerosis and enlargement of the skull at 4 weeks of age and appendicular bone enlargement at 10–13 weeks of age. Micro CT scans showed severe periosteal bone formation at the lateral aspect of the distal tibia and calcification of the calcaneus tendon. This model was used in the development of idursulfase for treatment of MPS II and may continue to be useful in the evaluation of treatment strategies of this chronic and progressive disorder.Keywords
This publication has 18 references indexed in Scilit:
- Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS IIMolecular Genetics and Metabolism, 2007
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 2006
- Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene deliveryHuman Molecular Genetics, 2006
- Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblastsThe Journal of Gene Medicine, 2005
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A diseaseHuman Molecular Genetics, 2003
- Enzyme Replacement Therapy in Feline Mucopolysaccharidosis IMolecular Genetics and Metabolism, 2001
- Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.Proceedings of the National Academy of Sciences, 1996
- Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.Journal of Clinical Investigation, 1989
- A canine model of human alpha-L-iduronidase deficiency.Proceedings of the National Academy of Sciences, 1983